

Carlo Ferrari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5010659/publications.pdf>

Version: 2024-02-01

117
papers

16,921
citations

20759

60
h-index

19690

117
g-index

119
all docs

119
docs citations

119
times ranked

11745
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B Virus Immunopathogenesis. Annual Review of Immunology, 1995, 13, 29-60.	9.5	1,550
2	The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Medicine, 1996, 2, 1104-1108.	15.2	804
3	Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection. Journal of Virology, 2007, 81, 4215-4225.	1.5	801
4	The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection. Journal of Experimental Medicine, 2000, 191, 1269-1280.	4.2	761
5	Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature, 1994, 369, 407-410.	13.7	572
6	PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion. Journal of Virology, 2006, 80, 11398-11403.	1.5	521
7	Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B. Gastroenterology, 2010, 138, 682-693.e4.	0.6	416
8	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	9.4	389
9	Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut, 2012, 61, 1754-1764.	6.1	387
10	T Cells with a CD4 + CD25 + Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8 + T Cells during Chronic Hepatitis C Virus Infection. Journal of Virology, 2005, 79, 7860-7867.	1.5	386
11	Adaptive immunity in HBV infection. Journal of Hepatology, 2016, 64, S71-S83.	1.8	358
12	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Science Translational Medicine, 2017, 9, .	5.8	343
13	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	3.7	342
14	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	1.8	341
15	Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology, 1999, 117, 1386-1396.	0.6	331
16	Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues. Gastroenterology, 2012, 143, 963-973.e9.	0.6	308
17	CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. European Journal of Immunology, 2000, 30, 2479-2487.	1.6	297
18	Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology, 2007, 45, 588-601.	3.6	266

#	ARTICLE	IF	CITATIONS
19	Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. <i>Nature Medicine</i> , 2017, 23, 327-336.	15.2	251
20	T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. <i>Hepatology</i> , 1994, 19, 286-295.	3.6	238
21	Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses. <i>Cancer Research</i> , 2006, 66, 1139-1146.	0.4	236
22	Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. <i>Journal of Hepatology</i> , 2003, 39, 595-605.	1.8	229
23	Kinetics of the immune response during HBV and HCV infection. <i>Hepatology</i> , 2003, 38, 4-13.	3.6	227
24	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	1.8	208
25	Interferon (IFN)-inducible Protein 10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN-2a and Ribavirin for Chronic Hepatitis C Virus Infection. <i>Journal of Infectious Diseases</i> , 2006, 194, 895-903.	1.9	201
26	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. <i>Hepatology</i> , 2006, 44, 1617-1625.	3.6	193
27	Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. <i>Hepatology</i> , 2006, 44, 126-139.	3.6	176
28	Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C. <i>Journal of Virology</i> , 2002, 76, 12423-12434.	1.5	168
29	Activation of Natural Killer Cells During Acute Infection With Hepatitis C Virus. <i>Gastroenterology</i> , 2010, 138, 1536-1545.	0.6	162
30	Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. <i>Vaccine</i> , 2007, 25, 8585-8597.	1.7	160
31	Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response. <i>Gastroenterology</i> , 2010, 138, 1931-1942.e2.	0.6	154
32	HBV and the immune response. <i>Liver International</i> , 2015, 35, 121-128.	1.9	153
33	Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine development. <i>Hepatology</i> , 1999, 30, 1088-1098.	3.6	150
34	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 68, 431-440.	1.8	147
35	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 43, 250-257.	1.8	143
36	Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2016, 65, 509-516.	1.8	142

#	ARTICLE	IF	CITATIONS
37	Heterologous T cell immunity in severe hepatitis C virus infection. <i>Journal of Experimental Medicine</i> , 2005, 201, 675-680.	4.2	134
38	Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms. <i>PLoS ONE</i> , 2011, 6, e17232.	1.1	131
39	TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(t)ide Analogues. <i>Gastroenterology</i> , 2018, 154, 1764-1777.e7.	0.6	123
40	Hepatitis B virus immunopathology. <i>Seminars in Immunopathology</i> , 1995, 17, 261-81.	4.0	120
41	The Characteristics of the Cell-Mediated Immune Response Identify Different Profiles of Occult Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2008, 134, 1470-1481.	0.6	115
42	Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire. <i>Journal of Virology</i> , 2008, 82, 10986-10997.	1.5	114
43	Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment. <i>Journal of Hepatology</i> , 2008, 48, 548-558.	1.8	113
44	Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. <i>Gastroenterology</i> , 2012, 143, 1576-1585.e4.	0.6	106
45	Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. <i>Hepatology</i> , 2010, 51, 1523-1530.	3.6	105
46	Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. <i>Gastroenterology</i> , 2019, 157, 227-241.e7.	0.6	99
47	The Host-Pathogen Interaction during HBV Infection: Immunological Controversies. <i>Antiviral Therapy</i> , 2010, 15, 15-24.	0.6	96
48	RNA Interference Therapy With ARCA520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	3.6	84
49	Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. <i>Journal of Clinical Investigation</i> , 2013, 123, 3766-3776.	3.9	80
50	Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches. <i>Frontiers in Immunology</i> , 2020, 11, 849.	2.2	79
51	Hepatitis B virus structure and biology. <i>Microbial Pathogenesis</i> , 1989, 6, 311-325.	1.3	78
52	Peginterferon- α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. <i>Journal of Hepatology</i> , 2012, 56, 1239-1246.	1.8	75
53	Natural killer cell phenotype modulation and natural killer/T cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. <i>Hepatology</i> , 2015, 62, 1697-1709.	3.6	73
54	Increased Immunostimulatory Activity Conferred to Antigen-presenting Cells by Exposure to Antigen Extract From Hepatocellular Carcinoma After Radiofrequency Thermal Ablation. <i>Journal of Immunotherapy</i> , 2008, 31, 271-282.	1.2	72

#	ARTICLE	IF	CITATIONS
55	Contribution of Herpesvirus Specific CD8 T Cells to Anti-Viral T Cell Response in Humans. PLoS Pathogens, 2010, 6, e1001051.	2.1	72
56	Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: Functional characterization in patients with chronic hepatitis C. Hepatology, 2002, 35, 1225-1236.	3.6	68
57	Immunopathogenesis of hepatitis B. Journal of Hepatology, 2003, 39, 36-42.	1.8	67
58	Ex vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+ cells in patients with hepatocellular carcinoma. Journal of Hepatology, 2004, 40, 102-109.	1.8	66
59	Increased Levels of Arginase in Patients With Acute Hepatitis B Suppress Antiviral T Cells. Gastroenterology, 2012, 143, 78-87.e3.	0.6	63
60	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	1.8	62
61	Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e32493.	1.1	61
62	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1 and G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. Annals of Surgical Oncology, 2016, 23, 981-989.	0.7	58
63	Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology, 2005, 41, 826-831.	3.6	57
64	The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection. Journal of Immunology, 2005, 175, 7519-7529.	0.4	57
65	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). Gastroenterology, 2007, 133, 1132-1143.	0.6	57
66	Viral determinants and host immune responses in the pathogenesis of HBV infection. Journal of Medical Virology, 2002, 67, 454-457.	2.5	55
67	Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. Hepatology, 2002, 36, 1446-1452.	3.6	53
68	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL and AASLD HBV Treatment Endpoints Conference. Hepatology, 2020, 71, 1070-1092.	3.6	52
69	Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut, 2012, 61, 1076-1084.	6.1	51
70	Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology, 1992, 103, 255-263.	0.6	50
71	Hepatitis C virus viremia following clinical resolution of acute hepatitis C. Journal of Hepatology, 1994, 20, 666-671.	1.8	49
72	Republished: Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Postgraduate Medical Journal, 2013, 89, 294-304.	0.9	49

#	ARTICLE	IF	CITATIONS
73	Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology. <i>Journal of Hepatology</i> , 2017, 67, 543-548.	1.8	48
74	HLA and Killer Immunoglobulin-like Receptor Genes as Outcome Predictors of Hepatitis C Virus-Related Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 5465-5473.	3.2	46
75	Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection. <i>Nature Communications</i> , 2020, 11, 604.	5.8	44
76	HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2754.	1.8	43
77	Identification of immunodominant hepatitis C virus (HCV)-specific cytotoxic T-cell epitopes by stimulation with endogenously synthesized HCV antigens. <i>Hepatology</i> , 2001, 33, 1533-1543.	3.6	40
78	The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5080.	1.8	39
79	Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. <i>Oncolmmunology</i> , 2016, 5, e1154249.	2.1	37
80	Strategies to overcome HBV-specific T cell exhaustion: checkpoint inhibitors and metabolic re-programming. <i>Current Opinion in Virology</i> , 2018, 30, 1-8.	2.6	36
81	The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. <i>Hepatology</i> , 2006, 43, 602-611.	3.6	35
82	Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 74, 783-793.	1.8	33
83	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. <i>BMC Gastroenterology</i> , 2012, 12, 11.	0.8	30
84	A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay. <i>Vaccines</i> , 2021, 9, 389.	2.1	30
85	A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 73-80.	0.6	29
86	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011, 43, 259-265.	0.4	29
87	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021, 160, 2483-2495.e26.	0.6	27
88	Immunopathogenesis of hepatitis C virus infection. <i>Journal of Hepatology</i> , 1999, 31, 31-38.	1.8	26
89	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2022, 71, 789-797.	6.1	25
90	Intratumor Regulatory Noncytotoxic NK Cells in Patients with Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 614.	1.8	24

#	ARTICLE	IF	CITATIONS
91	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.4	19
92	Long-term follow-up of anti-hepatitis C virus antibodies in patients with acute nonA nonB hepatitis and different outcome of liver disease. <i>Liver</i> , 1992, 12, 94-99.	0.1	17
93	Changes in Protein Expression in Two Cholangiocarcinoma Cell Lines Undergoing Formation of Multicellular Tumor Spheroids In Vitro. <i>PLoS ONE</i> , 2015, 10, e0118906.	1.1	16
94	Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1589-1603.	2.0	16
95	T cell regulation in HBV-related chronic liver disease. <i>Journal of Hepatology</i> , 2017, 66, 1096-1098.	1.8	14
96	Evaluation of monoclonality of cell lines from sequential dilution assays. <i>Journal of Immunological Methods</i> , 1987, 105, 139-143.	0.6	13
97	Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection. <i>Hepatology</i> , 2004, 40, 289-299.	3.6	13
98	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016, 48, 995-1005.	0.4	13
99	DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficient Virus Co-infection. <i>Clinical Infectious Diseases</i> , 2020, 73, e184-e190.	2.9	13
100	Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2013, 8, e56991.	1.1	12
101	Optimizing treatment of hepatic metastases from colorectal cancer: Resection or resection plus ablation?. <i>International Journal of Oncology</i> , 2016, 48, 1280-1289.	1.4	10
102	Metabolic regulation of the HBV-specific T cell function. <i>Antiviral Research</i> , 2021, 185, 104989.	1.9	9
103	Is antigenic variability a strategy adopted by hepatitis B virus to escape cytotoxic T-lymphocyte surveillance?. <i>Seminars in Virology</i> , 1996, 7, 23-30.	4.1	8
104	Therapeutic Vaccination for Hepatitis C: Can Protective T-Cell Responses Be Restored After Prolonged Antigen Exposure?. <i>Gastroenterology</i> , 2008, 134, 1601-1604.	0.6	7
105	Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon- α 2a/ribavirin therapy. <i>Journal of Hepatology</i> , 2008, 48, 932-938.	1.8	7
106	Aggressive Surgical Approach for Treatment of Primary and Recurrent Retroperitoneal Soft Tissue Sarcoma. <i>Indian Journal of Surgery</i> , 2018, 80, 154-162.	0.2	7
107	New perspectives for T-cell-based HCV vaccines. <i>Journal of Hepatology</i> , 2006, 45, 163-165.	1.8	6
108	T and B Cells in Hepatitis C Virus Control: What They Do and When They Fail. <i>Gastroenterology</i> , 2007, 132, 801-805.	0.6	6

#	ARTICLE	IF	CITATIONS
109	Predicting treatment outcome following 24 weeks peginterferon α -2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. <i>Hepatology</i> , 2007, 45, 258-259.	3.6	6
110	Comparative pathogenesis of HBV and HCV. <i>Virus Research</i> , 2001, 82, 19-23.	1.1	5
111	Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C. <i>Hepatology</i> , 2007, 45, 1333-1334.	3.6	3
112	Effects of the regulatory ligands calcium and GTP on the thermal stability of tissue transglutaminase. <i>Amino Acids</i> , 2012, 42, 2233-2242.	1.2	3
113	Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. <i>Journal of Medical Virology</i> , 2016, 88, 843-851.	2.5	3
114	Missed treatment in an Italian HBV infected patients cohort: HBV RER. <i>Digestive and Liver Disease</i> , 2016, 48, 1346-1350.	0.4	2
115	Targeting Stress Sensor Kinases in Hepatocellular Carcinoma-Infiltrating Human NK Cells as a Novel Immunotherapeutic Strategy for Liver Cancer. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
116	Mutual relationship between serum ferroxidase activity and hemoglobin levels in elderly individuals. <i>Annals of Hematology</i> , 2016, 95, 1333-1339.	0.8	1
117	Liver Resection or Resection plus Intraoperative Echo-Guided Ablation in the Treatment of Colorectal Metastases: We are Evaluating Their Effect for Cure. <i>American Surgeon</i> , 2018, 84, 1509-1517.	0.4	0